PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLenacapavir
Sunlenca(lenacapavir sodium)
Sunlenca (lenacapavir sodium) is a small molecule pharmaceutical. Lenacapavir sodium was first approved as Sunlenca on 2022-08-17. It is used to treat hiv-1 in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Sunlenca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lenacapavir sodium
Tradename
Company
Number
Date
Products
SUNLENCAGilead SciencesN-215973 RX2022-12-22
1 products, RLD, RS
SUNLENCAGilead SciencesN-215974 RX2022-12-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
sunlencaNew Drug Application2024-07-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv-1—D015497—
Agency Specific
FDA
EMA
Expiration
Code
LENACAPAVIR SODIUM, SUNLENCA, GILEAD SCIENCES INC
2027-12-22NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lenacapavir Sodium, Sunlenca, Gilead Sciences Inc
112677992038-08-16DP
100719852037-08-17DS, DP
106548272037-08-17U-3507
99510432034-02-28DS, DPU-3507
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AX: Other antivirals in atc
— J05AX31: Lenacapavir
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202108—118
InfectionsD007239EFO_0000544—123——5
Communicable diseasesD003141——123——5
Acquired immunodeficiency syndromeD000163EFO_0000765B20——2——2
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLenacapavir sodium
INNlenacapavir
Description
Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.
Classification
Small molecule
Drug classantivirals: viral capsid inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(C#Cc1ccc(-c2ccc(Cl)c3c([N-]S(C)(=O)=O)nn(CC(F)(F)F)c23)c([C@H](Cc2cc(F)cc(F)c2)NC(=O)Cn2nc(C(F)(F)F)c3c2C(F)(F)[C@@H]2C[C@H]32)n1)S(C)(=O)=O.[Na+]
Identifiers
PDB—
CAS-ID2283356-12-5
RxCUI—
ChEMBL IDCHEMBL4802249
ChEBI ID—
PubChem CID—
DrugBankDB15673
UNII IDA9A0O6FB4H (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 353 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
135 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use